Walnuts (Juglans regia) are one of the most nutritionally complex whole foods available, delivering a uniquely synergistic combination of plant-based omega-3 fatty acids (ALA), ellagitannin polyphenols, gamma-tocopherol, plant sterols, and bioactive peptides in a single whole-food matrix. Unlike most nuts, walnuts are the only commonly consumed nut with a meaningful ALA content, providing approximately 2.5g of omega-3 per 28g serving. They have been a core dietary staple in Persian, Greek, Roman, Ayurvedic, and Traditional Chinese medicine systems for millennia.

Walnuts exert their health effects through multiple simultaneous pathways: ALA is partially converted to EPA and DHA, supporting anti-inflammatory eicosanoid production and membrane fluidity in neuronal and cardiovascular tissues. Ellagitannins are metabolized by gut bacteria into urolithins, which have demonstrated anti-inflammatory and mitophagy-promoting effects in human studies. Plant sterols competitively inhibit intestinal cholesterol absorption, L-arginine supports endothelial nitric oxide synthesis for vasodilation, and gamma-tocopherol provides antioxidant protection against nitrogen-based reactive species not adequately neutralized by alpha-tocopherol.

Whole raw walnut halves are the most evidence-backed form, as clinical trials consistently use whole walnuts. Walnut oil retains ALA and tocopherols but loses most polyphenols and fiber. Walnut flour retains fiber and some polyphenols but has reduced fat-soluble nutrient content. Encapsulated walnut extract concentrates specific compounds (e.g., ellagitannins) but lacks the whole-food synergy demonstrated in trials. For cardiovascular and cognitive benefits, whole raw or lightly toasted walnuts are preferred.

• Cardiovascular disease risk
• Cognitive decline and brain health
• Type 2 diabetes and blood sugar regulation
• Systemic inflammation
• Gut microbiome health
• High cholesterol (dyslipidemia)
• Metabolic syndrome

• Cardiovascular events (supported by WAHA trial data and multiple prospective cohort studies showing reduced major cardiac event risk with regular walnut/nut consumption)
• Type 2 diabetes onset (supported by large prospective cohort data including the Nurses' Health Study and Health Professionals Follow-Up Study showing 20–30% lower diabetes risk with frequent nut consumption)
• Colorectal cancer (emerging evidence from observational data; ellagitannin-derived urolithins show anti-proliferative activity in human colon tissue — mechanistic support with epidemiological signal, not yet confirmed by RCT)
• Cognitive decline in older adults (supported by WAHA trial subgroup findings and prospective cohort data; effect strongest in individuals with lower baseline diet quality or cardiovascular risk factors)

• Whole raw walnuts (Juglans regia) — The primary food source; provides ~2.5g ALA, ~4g fiber, 4–5g polyphenols, and 185 calories per 28g (1 oz, ~14 halves) — the form used in virtually all human clinical trials.
• Black walnuts (Juglans nigra) — Native American species with higher protein content and slightly different polyphenol profile including higher juglone concentration; less studied clinically but nutritionally comparable to English walnut.
• Walnut oil (cold-pressed) — Concentrates ALA and gamma-tocopherol from walnuts; 14g provides ~8g of ALA — the highest plant-based ALA concentration of any common culinary oil. Lacks fiber and water-soluble polyphenols.
• Walnut butter — Whole ground walnuts retain most of the ALA, polyphenols, and fiber of whole walnuts in a spreadable form; minimally processed versions with no added oil preserve the full nutritional profile.
• Walnut flour (defatted) — Retains fiber, polyphenols, protein, and minerals from walnuts but much of the ALA is removed during fat extraction; useful for those seeking polyphenol and fiber benefits with lower caloric density.

• Tree nut allergy — ranging from oral allergy syndrome to anaphylaxis in sensitized individuals (most clinically significant risk)
• Gastrointestinal discomfort — bloating, loose stools, or cramping with sudden high intake due to fiber and fat content
• Caloric surplus if consumed in large quantities without substituting other calorie sources
• Rare: contact dermatitis from walnut skin or oil in topical use
• Juglone-containing walnut husks/leaves: not food-safe in large amounts; avoid medicinal use of hull/husk preparations without guidance

• Recommended daily: 28g (1 oz, approximately 14 walnut halves) per day — the dose used in the majority of clinical trials showing cardiovascular, cognitive, and metabolic benefits. Some trials used up to 43g/day with additional benefit and no adverse effects on weight.
• Best time of day: No specific time of day is mandated by clinical evidence. Many users find walnuts work well as a mid-morning or afternoon snack to leverage their satiety effect and prevent blood sugar fluctuations between meals.
• With or without food: Can be eaten alone or with meals. Including walnuts with or before a meal may slow glucose absorption from the meal and reduce postprandial glycemic response. Walnut oil is best used as a finishing oil (not high-heat cooking) to preserve ALA integrity.
• Time to effect: Lipid profile improvements (LDL, triglycerides) typically observed at 4–8 weeks. Cognitive and gut microbiome changes observed at 8–16 weeks. Endothelial function improvements documented as early as 4 weeks.
• How long to take it: Daily long-term consumption is supported and recommended — the WAHA trial demonstrated safety and benefit over 2 years of continuous daily consumption. No cycling is required. Consistent daily intake produces more reliable benefits than intermittent use.